Cybin Inc Q2 2026 Earnings Call: Strategic Advancements Amid Financial Challenges

Cybin Inc has completed enrollment for its Phase 2 CYB004 study, progressing Phase 3 studies for CYB003, and secured a $175 million financing. However, the company faces financial challenges with increased cash-based operating expenses and a net loss of $33.7 million. Additionally, a leadership transition is underway, and there is competition for resources at clinical trial sites. The CYB004 study aims for directional data and dose response, with top-line data expected in Q1 2026.